SUPNSupernus Pharmaceuticals, Inc.
Price
-7.3%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth steady, the market undecided.
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $219M in Q2 2026 (quarter ended Jun 30, 2026), up 32% from the same quarter a year earlier. That came with a gross margin of 85% and net loss of $58M. For the full year FY2025, revenue was $719M (+8.6% year on year) and net income −$39M. Its largest product in Q2 2026 was Qelbree at $89M, 41% of the disclosed total, well ahead of GOCOVRI at 17%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Filed by: Supernus Pharmaceuticals, Inc.Earnings release · press release
- Aug 3, 2026On August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) published a post relating to the proposed merger of equals of the Company and Indivior Pharmaceuticals Inc. (“Indivior”) on the Company’s LinkedIn account.Other event · Form 8-K
- Aug 3, 2026As previously announced, on August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) and Indivior Pharmaceuticals Inc. (“Indivior”) are hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger of the Company and Indivior.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $219.1MThe company’s own SEC segment disclosure.
- Qelbree$89.2M41%
- GOCOVRI$37.5M17%
- Collaboration$35.4M16%
- Royalty License And Other$18.0M8%
- ONAPGO$13.5M6%
- Oxtellar XR$8.8M4%
- Other (3)$16.6M8%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #21 of 41 by RyuScore